Medicare Enrolled
Dr. Vinaya Potluri, M.D.
Hematology & Oncology · Burleson, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Potluri from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Potluri?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Potluri
Dr. Vinaya Potluri is a hematology & oncology specialist in Burleson, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Potluri performed 70,944 Medicare services across 1,168 unique beneficiaries.
Between the years covered by Open Payments, Dr. Potluri received a total of $2,572 from 35 pharmaceutical and/or device companies across 76 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Potluri is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 13% volume in TX
$2,572 industry payments
Medicare Practice Summary
Medicare Utilization ↗70,944
Medicare services
Top 13% in TX for hematology & oncology
1,168
Unique beneficiaries
$4
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~3,734 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
52,500 | $1 | $3 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
7,200 | $0 | $5 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
5,750 | $6 | $28 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,345 | $0 | $5 |
| Anti-nausea injection (Aloxi/palonosetron) | 730 | $1 | $52 |
| COVID-19 test, self-administered An FDA-approved, authorized, or cleared test kit for nonprescription self-administered and self-collected use. This code represents the provision of one test count. |
451 | $12 | $30 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
335 | $91 | $275 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
265 | $7 | $300 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
253 | $135 | $350 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
250 | $12 | $70 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
233 | $11 | $60 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
211 | $101 | $412 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
203 | $65 | $175 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
164 | $23 | $100 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
113 | $48 | $190 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
101 | $1 | $10 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
100 | $92 | $250 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
97 | $51 | $202 |
| Principal care management for high-risk disease, first 30 minutes This service covers the initial 30 minutes of clinical staff time per calendar month to manage a single high-risk disease. It is directed by a healthcare professional. |
92 | $48 | $160 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
90 | $62 | $175 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
65 | $1 | $5 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
59 | $22 | $93 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
51 | $55 | $401 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
50 | $10 | $50 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
35 | $125 | $400 |
| CT scan of abdomen and pelvis with contrast A CT scan that uses dye to create detailed images of the abdomen and pelvis. This imaging test helps doctors examine internal organs and structures in these areas. |
34 | $159 | $681 |
| Additional 30 minutes of principal care management This service covers each additional 30 minutes of clinical staff time directed by a healthcare professional for managing a single high-risk disease, billed per calendar month. |
32 | $37 | $120 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
28 | $135 | $500 |
| New patient office visit, complex (60-74 min) | 25 | $159 | $500 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 24 | $106 | $450 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
22 | $49 | $150 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
21 | $1,160 | $4,069 |
| Advance care planning consultation, first 30 min A session focused on discussing and documenting future healthcare preferences and goals. This service covers the initial 30 minutes of the planning discussion. |
15 | $61 | $250 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
74.8% high complexity
22.7% medium
2.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$2,572
Total received (2018-2024)
Avg $367/year across 7 years
Bottom 45% in TX for hematology & oncology
35
Companies
76
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,524 (98.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$47 (1.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$289
2023
$637
2022
$105
2021
$325
2020
$194
2019
$310
2018
$711
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Daiichi Sankyo Inc.
$274
Celgene Corporation
$266
Astellas Pharma US Inc
$222
PFIZER INC.
$198
Takeda Pharmaceuticals U.S.A., Inc.
$164
Amgen Inc.
$160
PUMA BIOTECHNOLOGY, INC.
$136
Exelixis Inc.
$119
Puma Biotechnology, Inc.
$112
Janssen Biotech, Inc.
$98
Sirtex Medical Inc
$89
GlaxoSmithKline, LLC.
$84
E.R. Squibb & Sons, L.L.C.
$70
GENZYME CORPORATION
$59
AstraZeneca Pharmaceuticals LP
$42
ABBVIE INC.
$41
Myriad Genetic Laboratories, Inc.
$41
AngioDynamics, Inc.
$35
Novartis Pharmaceuticals Corporation
$35
Merck Sharp & Dohme LLC
$34
Kite Pharma, Inc.
$32
EMD Serono, Inc.
$28
Janssen Pharmaceuticals, Inc
$27
Pharmacyclics LLC, An AbbVie Company
$26
BeiGene USA, Inc.
$25
Agios Pharmaceuticals, Inc.
$21
Genentech USA, Inc.
$19
Eisai Inc.
$18
Seagen Inc.
$17
ARRAY BIOPHARMA INC
$15
Tempus AI, Inc
$14
Secura Bio, Inc.
$14
Acrotech Biopharma LLC
$12
Gilead Sciences, Inc.
$12
Lexicon Pharmaceuticals, Inc.
$12
Top 3 companies account for 29.6% of total payments
Associated products mentioned in payments ›
Abraxane · BELEODAQ · BLENREP · BOSULIF · BRUKINSA · Bavencio · CABLIVI · CALQUENCE · COPIKTRA · Cabometyx · DARZALEX · ENJAYMO · EPKINLY · Enhertu · Erleada · IBRANCE · IMBRUVICA · INLYTA · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · LUMAKRAS · LYNPARZA · Lenvima · NERLYNX · NINLARO · Nerlynx · Nplate · OJJAARA · PADCEV · PROMACTA · PYRUKYND · Pomalyst · REBLOZYL · SIR-Spheres Microspheres · SUTENT · TALZENNA · TECENTRIQ · TECVAYLI · VENCLEXTA · XALKORI · XARELTO · XTANDI · Xermelo · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $4 per 100 Medicare services performed
Geographic Context
Hematology & oncology specialists within 10 mi
36
Per 100K population
19.1
County median income
$81,826
Nearest hospital
BAYLOR SCOTT AND WHITE EMERGENCY HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Potluri is a mixed practice specialist, with above-average Medicare volume (top 13% in TX), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Potluri experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Potluri performed 52,500 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Potluri receive payments from pharmaceutical companies?
Yes. Dr. Potluri received a total of $2,572 from 35 companies across 76 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Potluri's costs compare to other hematology & oncology specialists in Burleson?
Dr. Potluri's average Medicare payment per service is $4. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Potluri) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Burleson
Browse hematology & oncology specialists in Burleson ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in TX
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in TX
Which TX hematology & oncology specialists receive the most from drug and device companies.
By company
Daiichi Sankyo Inc. Payments to Doctors
See all physicians who received payments from Daiichi Sankyo Inc.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology